Home » GENERICS HAIL NOVARTIS LOSS
GENERICS HAIL NOVARTIS LOSS
What could be a major setback to the Swiss drug maker Novartis has proven to
be a victory for the Indian pharmaceutical industry. After Novartis lost its
patent claim on Gleevec in India late last month, more than half a dozen Indian
drug companies are ready to launch the generic version of Imatinib Mesylate,
a lifesaving drug used to treat chronic myeloid leukemia, and tap the $100-million-plus
domestic market.
Red
Herring
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May